The short version of N-terminal modification fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-16. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
==== Prednisone ==== Prednisone is an immunosuppressive agent which affects all of the organ systems. Effects on the cellular level include cell activation, replication, differentiation, and mobility. The overall goal is to decrease blistering (inhibition of immediate and delayed hypersensitivity) through decreasing the production of autoantibodies. In order to suppress the production of antibodies, higher doses must be administered. Lesser doses can be prescribed in order to achieve suppression of monocyte function.
=== Chemistry of saturated vs unsaturated acids === The reactivity of saturated fatty acids is usually associated with the carboxylic acid or the adjacent methylene group. By conversion to their acid chlorides, they can be converted to the symmetrical fatty ketone laurone (O=C(CnH(2n+1))2). Treatment with sulfur trioxide gives the α-sulfonic acids. The reactivity of unsaturated fatty acids is often dominated by the site of unsaturation. These reactions are the basis of ozonolysis, hydrogenation, and the iodine number. Ozonolysis (degradation by ozone) is practiced in the production of azelaic acid ((CH2)7(CO2H)2) from oleic acid.
In captivity, these are not picky fish; They readily feed on different types of frozen, freeze-dried and live foods, such as tubifex worms, bean beetles (and larvae), bloodworms, brine shrimp, daphnia, flour beetles, krill, springtails, small or finely-chopped earthworms, black soldier fly larvae and cultured wingless fruit flies (Drosophila melanogaster). In particular, the tubifex worms and fruit flies are high in protein and nutrients, resulting in highly significant growth. A predominantly live food diet also provides nutrients for better reproductive performance. Ultimately, food variety is key, for health, but also for mimicking natural feeding habits. It was first described by Ferdinand Schultze in a catalog of specimens at the Zoological Museum of the Royal University of Berlin, published by Hinrich Lichtenstein in 1823. First import to Europe (Germany) by C.Ziggelkow, Hamburg in 1909 The genome of the angelfish was sequenced and assembled in 2022 by Indeever Madireddy, a high school student.
Sources: en.wikipedia.org
The chain catshark or chain dogfish (Scyliorhinus retifer) is a small, reticulated catshark that is biofluorescent. The species is common in the Northwest Atlantic, Gulf of Mexico, and Caribbean. It is harmless and rarely encountered by humans. It has very similar reproductive traits to the small-spotted catshark (S. canicula).
== SI == si – (s) Sinhala language (ISO 639-1 code) Si – (s) Silicon SI (s) Slovenia (ISO 3166 and FIPS 10-4 country code digram) (i) Socialist International Sports Illustrated Système International (French, International System of Units) SIA – (s) Singapore Airlines (ICAO code) SIA – (i) Survivors of Incest Anonymous SIAM – (i) Society for Industrial and Applied Mathematics SIC – (a) Standard Industrial Classification SICS – (a/i) Swedish Institute of Computer Science SIDS – (a) Sudden infant death syndrome SIDU – (i) select, insert, delete, update. See Create, read, update and delete SIF – (i) Selective Identification Feature SIFF – (i) Successor IFF SIG (i) Schweizerische Industrie Gesellschaft (German, "Swiss Industry Company"). See also SIG Sauer, a firearms manufacturer spun off from the aforementioned company in 2000.
== History == Beginning with William Harvey's experiments on the circulation of blood, recorded research into blood transfusion began in the 17th century, with successful experiments in transfusion between animals. However, successive attempts by physicians to transfuse animal blood into humans gave variable, often fatal, results.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.